BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, February 10, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 27, 2012
View Archived Issues
New data support Tmprss6 as a therapeutic target for beta-thalassemia and hereditary hemochromatosis
Read More
U.S. researchers design novel heterodimeric targeting ligands
Read More
Ironwood Pharmaceuticals begins phase I trial of antianxiety drug candidate
Read More
Halozyme Therapeutics and Pfizer to develop recombinant human hyaluronidase biologics
Read More
Phase II TO-2061 trial in OCD does not meet primary endpoint
Read More
A new vaccine target identified for the treatment of parasitic Schistosomiasis
Read More
Novel alpha7 nAChR receptor agonist designed by Siena Biotech and Pfizer
Read More
Endo returns global rights for Urocidin
Read More
Novel diagnostic agents for AD patented by Nihon Medi-Physics
Read More
Catabasis Pharmaceuticals presents new GABA conjugates
Read More
Spectrum Pharmaceuticals' pivotal BELIEF trial meets primary endpoint
Read More
Novel agents for obesity disclosed by GlaxoSmithKline
Read More
Researchers at Merck & Co. patent new PDE10A inhibitors
Read More
Ranbaxy Laboratories presents new DPP IV inhibitor for the treatment of diabetes
Read More
The Wistar Institute divulges new EBNA-1 protein inhibitors
Read More
Two novel mutations identified in patient with cyclic neutropenia
Read More
Raptor Pharmaceutical provides update on NDA review for Procysbi
Read More
Recommendations presented by AAC on Ampligen for chronic fatigue syndrome
Read More
U.K. regulators set to approve Horizon Pharma's MAA for Duexis
Read More
Only For Children Pharmaceuticals withdraws MAA for Loulla
Read More
Cubist submits supplemental NDA to FDA for Entereg
Read More
FDA approves Juxtapid for homozygous familial hypercholesterolemia
Read More
A dual SYK/JAK inhibitor shows potential in animal models of arthritis and B-cell malignancies
Read More
Acorda Therapeutics completes acquisition of Neuronex
Read More
Sarepta Therapeutics enters into influenza trial agreement with the NIAID
Read More
Once-monthly formulation of antiosteoporotic agent approved in Japan
Read More
Results published from phase II trial of immunocytokine therapy in melanoma
Read More
